← Back to Search

Brachytherapy

Radiation Therapies for Prostate Cancer

N/A
Waitlist Available
Led By Peter Chung, MB ChB
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients will be one of the following risk groups prior to therapy:
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial is testing whether or not delivering radiation to a specific area in the prostate, as seen on MRI, at a higher than normal dose is safe and effective.

Eligible Conditions
  • Prostate Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Before starting treatment, you need to have certain risk factors.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine rates of Local Control after standard targeted boost radiotherapy in patients with localized prostate cancer.
Secondary outcome measures
Assess Quality of Life (QoL) outcomes after high-dose tumor-targeted boost therapy.
Compare dose to recurrent and non-recurrent tumor nodules.
Determine a methodology with appropriate uncertainty margins for Gross Tumour Volume boost
+6 more
Other outcome measures
Biopsy
Explore the predictive value of baseline and early response imaging biomarkers on Local Control.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Prior Radiation Treatment (Control Cohort)Experimental Treatment1 Intervention
Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
Group II: Active Radiation Treatment (Cohort 2)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,456 Previous Clinical Trials
482,714 Total Patients Enrolled
63 Trials studying Prostate Cancer
15,355 Patients Enrolled for Prostate Cancer
Princess Margaret Hospital, CanadaOTHER
118 Previous Clinical Trials
38,609 Total Patients Enrolled
8 Trials studying Prostate Cancer
9,455 Patients Enrolled for Prostate Cancer
Peter Chung, MB ChBPrincipal InvestigatorUniversity Health Network, The Princess Margaret
3 Previous Clinical Trials
512 Total Patients Enrolled

Media Library

High-Dose Rate (HDR) Radiotherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01802242 — N/A
Prostate Cancer Research Study Groups: Active Radiation Treatment (Cohort 2), Prior Radiation Treatment (Control Cohort)
Prostate Cancer Clinical Trial 2023: High-Dose Rate (HDR) Radiotherapy Highlights & Side Effects. Trial Name: NCT01802242 — N/A
High-Dose Rate (HDR) Radiotherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01802242 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this inquiry currently recruiting participants?

"Per clinicaltrials.gov, this medical study is not actively enrolling volunteers at the moment. Originally posted in October 1st 2012 and last updated on 20th 2022, it has ceased its recruitment process; however there are 1322 other trials that continue to search for participants."

Answered by AI
~7 spots leftby Mar 2025